Press releases
- Eupraxia Pharmaceuticals to Present at Controlled Release Society 2024 Annual Meeting and Expo
- Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
- Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
- Eupraxia Pharmaceuticals to Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
- Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
- Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
- Eupraxia Pharmaceuticals to Present Initial Results from Ongoing Phase 1b Study of EP-104GI for the Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
- Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Eupraxia Pharmaceuticals Announces Gastrointestinal Clinical Advisory Board
More ▼
Key statistics
On Monday, Eupraxia Pharmaceuticals Inc (EPRX:NAQ) closed at 2.82, 17.40% above the 52 week low of 2.40 set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.82 |
---|---|
High | 2.90 |
Low | 2.65 |
Bid | -- |
Offer | -- |
Previous close | 2.61 |
Average volume | 16.68k |
---|---|
Shares outstanding | 35.62m |
Free float | 33.15m |
P/E (TTM) | -- |
Market cap | 138.75m CAD |
EPS (TTM) | -1.68 CAD |
Data delayed at least 15 minutes, as of Jul 29 2024 20:59 BST.
More ▼